Glenmark Issues Recall On 114 Batches Due To Life-Threatening Risk
Glenmark recalls 114 batches of 750mg potassium chloride capsules over dissolution issues and hyperkalemia risk.
Glenmark Pharmaceuticals announced a recall of 114 batches
of 750mg potassium chloride extended-release capsules due to issues with their
dissolution. This recall stems from concerns that incomplete dissolution could
lead to elevated potassium levels, known as hyperkalemia, which can trigger
irregular heartbeats and potentially cardiac arrest.
These capsules are typically prescribed to treat low
potassium levels (hypokalemia) in patients, especially those with conditions
like hypertension, heart failure, or kidney dysfunction. Glenmark emphasized
the risk of developing hyperkalemia among users, highlighting potential severe
adverse effects, including life-threatening complications.
The affected batches were distributed nationwide in the
U.S., with expiry dates ranging from June 2024 to September 2025. This recall
follows Glenmark's recent efforts to manage financial challenges, including a
significant debt reduction strategy announced last year involving the sale of a
major portion of its pharmaceutical ingredient business.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion